We aimed to investigate the predictive value of
microRNA 103 (MIR103) and
microRNA 107 (MIR107) for
acute respiratory distress syndrome (ARDS) risk, as well as their correlations with overall disease severity and prognosis in
sepsis patients.Plasma samples were collected from 196
sepsis patients within 24 hours after enrollment and from 196 healthy individuals (as healthy controls (HCs)) at enrollment. Plasma MIR103 and MIR107 were detected by reverse transcription-quantitative polymerase chain reaction.MIR103 and MIR107 were both decreased in ARDS
sepsis patients and non-ARDS
sepsis patients compared to HCs, and were reduced in ARDS
sepsis patients than non-ARDS
sepsis patients. Decreased MIR103 (area under curve (AUC): 0.727, 95% confidence interval (CI): 0.619-0.835) and MIR107 (AUC: 0.694, 95% CI: 0.577-0.811) predicted increased ARDS risk in
sepsis patients. Meanwhile, MIR103 and MIR107 were negatively correlated with acute pathologic and chronic health evaluation (APACHE) II score, sequential organ failure assessment (SOFA) score, serum
creatinine,
C-reactive protein,
tumor necrosis factor,
interleukin 1β,
interleukin 6 and
interleukin 8, while positively correlated with
albumin in
sepsis patients. For prognosis, 28-day mortality was increased in ARDS
sepsis patients compared to non-ARDS
sepsis patients. Finally, MIR103 and MIR107 were reduced in deaths than survivors of
sepsis patients, and decreased MIR103 (AUC: 0.704, 95% CI: 0.626-0.782) as well as MIR107 (AUC: 0.649, 95% CI: 0.569-0.729) predicted increased 28-day mortality risk in
sepsis patients.MiR-103 and MIR107 were predictive
biomarkers for risks of ARDS and 28-day mortality in
sepsis patients, which might improve the management of
sepsis.